Not Available

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: N43CO201000095
Agency Tracking Number: N43CO201000095
Amount: $299,881.00
Phase: Phase I
Program: SBIR
Awards Year: 2010
Solitcitation Year: 2010
Solitcitation Topic Code: NCI
Solitcitation Number: PHS2010-1
Small Business Information
182 ELM ST, UNIT 3, CAMBRIDGE, MA, 02139-
Duns: 829731814
Hubzone Owned: N
Woman Owned: Y
Socially and Economically Disadvantaged: N
Principal Investigator
 Magdalena Leszczyniecka
 (617) 899-0724
Business Contact
Phone: (617) 899-0724
Research Institution
The goal of this project is to develop STC trastuzumab, a generic version of Herceptin. Trastuzumab is a monoclonal antibody made against the HER2 protein that is overexpressed in 20-25% of patients with breast cancer. Because of very high cost associated with prescribing Herceptin, a generic version of this drug would make cancer treatment more affordable to a wider segment of the population and lower the cost burden on government-sponsored healthcare programs. STC Biologics Inc. is uniquely positioned to address the technical challenge of reverse engineering trastuzumab as its drug development platform offers rapid and efficient analysis of post-translational modification of recombinant proteins.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government